Compare GKOS & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GKOS | HLNE |
|---|---|---|
| Founded | 1998 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 5.4B |
| IPO Year | 2015 | 2017 |
| Metric | GKOS | HLNE |
|---|---|---|
| Price | $116.08 | $134.33 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $125.54 | ★ $160.89 |
| AVG Volume (30 Days) | ★ 865.8K | 569.2K |
| Earning Date | 10-29-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 1.61% |
| EPS Growth | N/A | ★ 19.80 |
| EPS | N/A | ★ 5.55 |
| Revenue | $469,820,000.00 | ★ $733,070,000.00 |
| Revenue This Year | $31.15 | $8.42 |
| Revenue Next Year | $24.15 | $19.65 |
| P/E Ratio | ★ N/A | $24.24 |
| Revenue Growth | ★ 30.38 | 13.01 |
| 52 Week Low | $73.16 | $111.98 |
| 52 Week High | $163.71 | $179.19 |
| Indicator | GKOS | HLNE |
|---|---|---|
| Relative Strength Index (RSI) | 76.42 | 63.76 |
| Support Level | $105.88 | $127.92 |
| Resistance Level | $116.72 | $135.56 |
| Average True Range (ATR) | 3.26 | 3.80 |
| MACD | 0.07 | 0.88 |
| Stochastic Oscillator | 94.61 | 91.56 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.